Industry Research Reports

Home > Reports > Service & Software > Global Artificial Intelligence in Pharma and Biotech Market Outlook, In‑Depth Analysis & Forecast to 2032

Global Artificial Intelligence in Pharma and Biotech Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Service & Software

Published Date: 2026-07-30

Pages: 170 Pages

Report ld: 6982944

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Artificial Intelligence in Pharma and Biotech Market Size(US$)

CAGR 2026-2032

31.0%

Market Size,2032

USD 18,011

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 3,560 million

Market Forecast in 2032(Value)

US$ 18,011 million

CAGR

31.0%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Artificial Intelligence in Pharma and Biotech market is projected to grow from US$ 2130 million in 2025 to US$ 18011 million by 2032, at a CAGR of 31.0% (2026-2032), driven by critical product segments and diverse end‑use applications.

Artificial Intelligence in Pharma and Biotech refers to the application of artificial intelligence technologies in pharmaceutical, biotechnology, and life science research and commercialization processes. By utilizing technologies such as machine learning, deep learning, natural language processing (NLP), generative AI, computer vision, and knowledge graphs, AI systems analyze and process biomedical data, clinical information, molecular structures, and scientific literature to improve drug discovery efficiency, optimize clinical development, accelerate research and development processes, and reduce development costs. Key applications of AI in pharmaceutical and biotechnology industries include AI-driven drug discovery, target identification and validation, molecular design and optimization, protein structure prediction, clinical trial design and patient recruitment optimization, biomarker discovery, scientific literature analysis, and pharmaceutical manufacturing quality control. AI enables pharmaceutical and biotechnology companies to shorten drug development timelines, improve the accuracy of candidate drug screening, and accelerate advances in precision medicine, personalized therapies, and next-generation biopharmaceutical development.

From a downstream perspective, Oncology accounted for % of 2025 revenue, surging to US$ million by 2032 (CAGR: % from 2026–2032).

Artificial Intelligence in Pharma and Biotech leading players (including AstraZeneca, Thales Group, IBM Corp., ForeSee Medical, Atomwise, Cloud Pharmaceuticals, GNS Healthcare, Microsoft Corporation, Novartis AG, NVIDIA Corporation, etc.), dominate supply; the top five capture approximately % of global revenue, with AstraZeneca leading 2025 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2025 to a forecast US$ million by 2032 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2025, % share rising to % by 2032), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2032 (CAGR %).

MARKET SEGMENTATION

By Company

AstraZeneca
Thales Group
IBM Corp.
ForeSee Medical
Atomwise
Cloud Pharmaceuticals
GNS Healthcare
Microsoft Corporation
Novartis AG
NVIDIA Corporation
Pfizer
Recursion Pharmaceuticals
XtalPi Inc
Aidoc
AliveCor
GE Healthcare
Imagen Technologies
Vuno Inc.
IDx Technologies Inc.
Siemens Healthcare GmbH
Neural Analytics
Insilico Medicine

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

AI Drug Discovery
Preclinical Research AI
Clinical Trial AI
Others

Segment by Application

Oncology
Neurology
Immunology
Rare Diseases
Infectious Diseases
Others

Segment by Category

Machine Learning
Deep Learning
Generative AI
Computer Vision
Others

biaoTi REPORT SCOPE

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Artificial Intelligence in Pharma and Biotech market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Artificial Intelligence in Pharma and Biotech study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application

Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles

Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments

Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Artificial Intelligence in Pharma and Biotech: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Artificial Intelligence in Pharma and Biotech Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 AI Drug Discovery

1.2.3 Preclinical Research AI

1.2.4 Clinical Trial AI

1.2.5 Others

1.3 Market Segmentation by Technology

1.3.1 Global Artificial Intelligence in Pharma and Biotech Market Size by Technology, 2021 vs 2025 vs 2032

1.3.2 Machine Learning

1.3.3 Deep Learning

1.3.4 Generative AI

1.3.5 Computer Vision

1.3.6 Others

1.4 Market Segmentation by Application

1.4.1 Global Artificial Intelligence in Pharma and Biotech Market Size by Application, 2021 vs 2025 vs 2032

1.4.2 Oncology

1.4.3 Neurology

1.4.4 Immunology

1.4.5 Rare Diseases

1.4.6 Infectious Diseases

1.4.7 Others

1.5 Assumptions and Limitations

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global Artificial Intelligence in Pharma and Biotech Revenue Estimates and Forecasts (2021-2032)

2.2 Global Artificial Intelligence in Pharma and Biotech Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape

3.1 Global Artificial Intelligence in Pharma and Biotech Players’ Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2021-2026)

3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Players (2021 vs 2025)

3.2 Global Artificial Intelligence in Pharma and Biotech Companies Headquarters and Service Footprint

3.3 Key Player Market Share by Product Type

3.3.1 AI Drug Discovery: Market Share by Key Players

3.3.2 Preclinical Research AI: Market Share by Key Players

3.3.3 Clinical Trial AI: Market Share by Key Players

3.3.4 Others: Market Share by Key Players

3.4 Global Artificial Intelligence in Pharma and Biotech Market Concentration and Dynamics

3.4.1 Global Market Concentration

3.4.2 Market Entry and Exit Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation

4.1 Global Artificial Intelligence in Pharma and Biotech Market by Type

4.1.1 Global Revenue by Type (2021-2032)

4.1.2 Global Revenue-Based Market Share by Type (2021-2032)

4.2 Global Artificial Intelligence in Pharma and Biotech Market by Technology

4.2.1 Global Revenue by Technology (2021-2032)

4.2.2 Global Revenue-Based Market Share by Technology (2021-2032)

4.3 Key Product Attributes and Differentiation

4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.4.1 High-Growth Niches and Adoption Drivers

4.4.2 Profitability Hotspots and Cost Drivers

4.4.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global Artificial Intelligence in Pharma and Biotech Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)

5.1.2 Revenue-Based Market Share by Application (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2021-2032)

6.2 North America Key Players’ Revenue in 2025

6.3 North America Artificial Intelligence in Pharma and Biotech Market Size by Application (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America Artificial Intelligence in Pharma and Biotech Market Size by Country

6.5.1 North America Revenue Trends by Country

6.5.2 US

6.5.3 Canada

6.5.4 Mexico

7 Europe

7.1 Europe Market Size (2021-2032)

7.2 Europe Key Players’ Revenue in 2025

7.3 Europe Artificial Intelligence in Pharma and Biotech Market Size by Application (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe Artificial Intelligence in Pharma and Biotech Market Size by Country

7.5.1 Europe Revenue Trends by Country

7.5.2 Germany

7.5.3 France

7.5.4 U.K.

7.5.5 Italy

7.5.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2021-2032)

8.2 Asia-Pacific Key Players’ Revenue in 2025

8.3 Asia-Pacific Artificial Intelligence in Pharma and Biotech Market Size by Application (2021-2032)

8.4 Asia-Pacific Growth Accelerators and Market Barriers

8.5 Asia-Pacific Artificial Intelligence in Pharma and Biotech Market Size by Region

8.5.1 Asia-Pacific Revenue Trends by Region

8.6 China

8.7 Japan

8.8 South Korea

8.9 Australia

8.10 India

8.11 Southeast Asia

8.11.1 Indonesia

8.11.2 Vietnam

8.11.3 Malaysia

8.11.4 Philippines

8.11.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2021-2032)

9.2 Central and South America Key Players’ Revenue in 2025

9.3 Central and South America Artificial Intelligence in Pharma and Biotech Market Size by Application (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America Artificial Intelligence in Pharma and Biotech Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2021-2032)

10.2 Middle East and Africa Key Players’ Revenue in 2025

10.3 Middle East and Africa Artificial Intelligence in Pharma and Biotech Market Size by Application (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa Artificial Intelligence in Pharma and Biotech Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Israel

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 AstraZeneca

11.1.1 AstraZeneca Corporation Information

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.1.4 AstraZeneca Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.1.5 AstraZeneca Artificial Intelligence in Pharma and Biotech Revenue by Product in 2025

11.1.6 AstraZeneca Artificial Intelligence in Pharma and Biotech Revenue by Application in 2025

11.1.7 AstraZeneca Artificial Intelligence in Pharma and Biotech Revenue by Geographic Area in 2025

11.1.8 AstraZeneca Artificial Intelligence in Pharma and Biotech SWOT Analysis

11.1.9 AstraZeneca Recent Developments

11.2 Thales Group

11.2.1 Thales Group Corporation Information

11.2.2 Thales Group Business Overview

11.2.3 Thales Group Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.2.4 Thales Group Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.2.5 Thales Group Artificial Intelligence in Pharma and Biotech Revenue by Product in 2025

11.2.6 Thales Group Artificial Intelligence in Pharma and Biotech Revenue by Application in 2025

11.2.7 Thales Group Artificial Intelligence in Pharma and Biotech Revenue by Geographic Area in 2025

11.2.8 Thales Group Artificial Intelligence in Pharma and Biotech SWOT Analysis

11.2.9 Thales Group Recent Developments

11.3 IBM Corp.

11.3.1 IBM Corp. Corporation Information

11.3.2 IBM Corp. Business Overview

11.3.3 IBM Corp. Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.3.4 IBM Corp. Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.3.5 IBM Corp. Artificial Intelligence in Pharma and Biotech Revenue by Product in 2025

11.3.6 IBM Corp. Artificial Intelligence in Pharma and Biotech Revenue by Application in 2025

11.3.7 IBM Corp. Artificial Intelligence in Pharma and Biotech Revenue by Geographic Area in 2025

11.3.8 IBM Corp. Artificial Intelligence in Pharma and Biotech SWOT Analysis

11.3.9 IBM Corp. Recent Developments

11.4 ForeSee Medical

11.4.1 ForeSee Medical Corporation Information

11.4.2 ForeSee Medical Business Overview

11.4.3 ForeSee Medical Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.4.4 ForeSee Medical Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.4.5 ForeSee Medical Artificial Intelligence in Pharma and Biotech Revenue by Product in 2025

11.4.6 ForeSee Medical Artificial Intelligence in Pharma and Biotech Revenue by Application in 2025

11.4.7 ForeSee Medical Artificial Intelligence in Pharma and Biotech Revenue by Geographic Area in 2025

11.4.8 ForeSee Medical Artificial Intelligence in Pharma and Biotech SWOT Analysis

11.4.9 ForeSee Medical Recent Developments

11.5 Atomwise

11.5.1 Atomwise Corporation Information

11.5.2 Atomwise Business Overview

11.5.3 Atomwise Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.5.4 Atomwise Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.5.5 Atomwise Artificial Intelligence in Pharma and Biotech Revenue by Product in 2025

11.5.6 Atomwise Artificial Intelligence in Pharma and Biotech Revenue by Application in 2025

11.5.7 Atomwise Artificial Intelligence in Pharma and Biotech Revenue by Geographic Area in 2025

11.5.8 Atomwise Artificial Intelligence in Pharma and Biotech SWOT Analysis

11.5.9 Atomwise Recent Developments

11.6 Cloud Pharmaceuticals

11.6.1 Cloud Pharmaceuticals Corporation Information

11.6.2 Cloud Pharmaceuticals Business Overview

11.6.3 Cloud Pharmaceuticals Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.6.4 Cloud Pharmaceuticals Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.6.5 Cloud Pharmaceuticals Recent Developments

11.7 GNS Healthcare

11.7.1 GNS Healthcare Corporation Information

11.7.2 GNS Healthcare Business Overview

11.7.3 GNS Healthcare Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.7.4 GNS Healthcare Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.7.5 GNS Healthcare Recent Developments

11.8 Microsoft Corporation

11.8.1 Microsoft Corporation Corporation Information

11.8.2 Microsoft Corporation Business Overview

11.8.3 Microsoft Corporation Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.8.4 Microsoft Corporation Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.8.5 Microsoft Corporation Recent Developments

11.9 Novartis AG

11.9.1 Novartis AG Corporation Information

11.9.2 Novartis AG Business Overview

11.9.3 Novartis AG Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.9.4 Novartis AG Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.9.5 Novartis AG Recent Developments

11.10 NVIDIA Corporation

11.10.1 NVIDIA Corporation Corporation Information

11.10.2 NVIDIA Corporation Business Overview

11.10.3 NVIDIA Corporation Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.10.4 NVIDIA Corporation Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.10.5 Company Ten Recent Developments

11.11 Pfizer

11.11.1 Pfizer Corporation Information

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.11.4 Pfizer Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.11.5 Pfizer Recent Developments

11.12 Recursion Pharmaceuticals

11.12.1 Recursion Pharmaceuticals Corporation Information

11.12.2 Recursion Pharmaceuticals Business Overview

11.12.3 Recursion Pharmaceuticals Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.12.4 Recursion Pharmaceuticals Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.12.5 Recursion Pharmaceuticals Recent Developments

11.13 XtalPi Inc

11.13.1 XtalPi Inc Corporation Information

11.13.2 XtalPi Inc Business Overview

11.13.3 XtalPi Inc Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.13.4 XtalPi Inc Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.13.5 XtalPi Inc Recent Developments

11.14 Aidoc

11.14.1 Aidoc Corporation Information

11.14.2 Aidoc Business Overview

11.14.3 Aidoc Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.14.4 Aidoc Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.14.5 Aidoc Recent Developments

11.15 AliveCor

11.15.1 AliveCor Corporation Information

11.15.2 AliveCor Business Overview

11.15.3 AliveCor Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.15.4 AliveCor Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.15.5 AliveCor Recent Developments

11.16 GE Healthcare

11.16.1 GE Healthcare Corporation Information

11.16.2 GE Healthcare Business Overview

11.16.3 GE Healthcare Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.16.4 GE Healthcare Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.16.5 GE Healthcare Recent Developments

11.17 Imagen Technologies

11.17.1 Imagen Technologies Corporation Information

11.17.2 Imagen Technologies Business Overview

11.17.3 Imagen Technologies Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.17.4 Imagen Technologies Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.17.5 Imagen Technologies Recent Developments

11.18 Vuno Inc.

11.18.1 Vuno Inc. Corporation Information

11.18.2 Vuno Inc. Business Overview

11.18.3 Vuno Inc. Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.18.4 Vuno Inc. Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.18.5 Vuno Inc. Recent Developments

11.19 IDx Technologies Inc.

11.19.1 IDx Technologies Inc. Corporation Information

11.19.2 IDx Technologies Inc. Business Overview

11.19.3 IDx Technologies Inc. Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.19.4 IDx Technologies Inc. Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.19.5 IDx Technologies Inc. Recent Developments

11.20 Siemens Healthcare GmbH

11.20.1 Siemens Healthcare GmbH Corporation Information

11.20.2 Siemens Healthcare GmbH Business Overview

11.20.3 Siemens Healthcare GmbH Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.20.4 Siemens Healthcare GmbH Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.20.5 Siemens Healthcare GmbH Recent Developments

11.21 Neural Analytics

11.21.1 Neural Analytics Corporation Information

11.21.2 Neural Analytics Business Overview

11.21.3 Neural Analytics Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.21.4 Neural Analytics Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.21.5 Neural Analytics Recent Developments

11.22 Insilico Medicine

11.22.1 Insilico Medicine Corporation Information

11.22.2 Insilico Medicine Business Overview

11.22.3 Insilico Medicine Artificial Intelligence in Pharma and Biotech Product Features and Attributes

11.22.4 Insilico Medicine Artificial Intelligence in Pharma and Biotech Revenue and Gross Margin (2021-2026)

11.22.5 Insilico Medicine Recent Developments

12 Artificial Intelligence in Pharma and Biotech Value Chain and Ecosystem Analysis

12.1 Artificial Intelligence in Pharma and Biotech Value Chain (Ecosystem Structure)

12.2 Upstream Analysis

12.2.1 Key Technologies, Platforms and Infrastructure

12.3 Midstream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Artificial Intelligence in Pharma and Biotech Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Artificial Intelligence in Pharma and Biotech Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Technology, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global Artificial Intelligence in Pharma and Biotech Revenue by Region (US$ Million), 2021-2026

Table 6. Global Artificial Intelligence in Pharma and Biotech Revenue by Region (US$ Million), 2027-2032

Table 7. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 8. Global Artificial Intelligence in Pharma and Biotech Revenue by Players (US$ Million), 2021-2026

Table 9. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share by Players (2021-2026)

Table 10. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)

Table 11. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Artificial Intelligence in Pharma and Biotech Revenue, 2025

Table 12. Global Artificial Intelligence in Pharma and Biotech Average Gross Margin (%) by Player (2021 vs 2025)

Table 13. Global Artificial Intelligence in Pharma and Biotech Companies Headquarters

Table 14. Global Artificial Intelligence in Pharma and Biotech Market Concentration Ratio (CR5)

Table 15. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 16. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 17. Global Artificial Intelligence in Pharma and Biotech Revenue by Type (US$ Million), 2021-2026

Table 18. Global Artificial Intelligence in Pharma and Biotech Revenue by Type (US$ Million), 2027-2032

Table 19. Global Artificial Intelligence in Pharma and Biotech Revenue by Technology (US$ Million), 2021-2026

Table 20. Global Artificial Intelligence in Pharma and Biotech Revenue by Technology (US$ Million), 2027-2032

Table 21. Key Product Attributes and Differentiation

Table 22. Global Artificial Intelligence in Pharma and Biotech Revenue by Application (US$ Million), 2021-2026

Table 23. Global Artificial Intelligence in Pharma and Biotech Revenue by Application (US$ Million), 2027-2032

Table 24. Artificial Intelligence in Pharma and Biotech High-Growth Sectors Demand CAGR (2026-2032)

Table 25. Top Customers by Region

Table 26. Top Customers by Application

Table 27. North America Artificial Intelligence in Pharma and Biotech Growth Accelerators and Market Barriers

Table 28. North America Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 29. Europe Artificial Intelligence in Pharma and Biotech Growth Accelerators and Market Barriers

Table 30. Europe Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Asia-Pacific Artificial Intelligence in Pharma and Biotech Growth Accelerators and Market Barriers

Table 32. Asia-Pacific Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Central and South America Artificial Intelligence in Pharma and Biotech Investment Opportunities and Key Challenges

Table 34. Central and South America Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 35. Middle East and Africa Artificial Intelligence in Pharma and Biotech Investment Opportunities and Key Challenges

Table 36. Middle East and Africa Artificial Intelligence in Pharma and Biotech Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 37. AstraZeneca Corporation Information

Table 38. AstraZeneca Description and Major Businesses

Table 39. AstraZeneca Product Features and Attributes

Table 40. AstraZeneca Revenue (US$ Million) and Gross Margin (2021-2026)

Table 41. AstraZeneca Revenue Proportion by Product in 2025

Table 42. AstraZeneca Revenue Proportion by Application in 2025

Table 43. AstraZeneca Revenue Proportion by Geographic Area in 2025

Table 44. AstraZeneca Artificial Intelligence in Pharma and Biotech SWOT Analysis

Table 45. AstraZeneca Recent Developments

Table 46. Thales Group Corporation Information

Table 47. Thales Group Description and Major Businesses

Table 48. Thales Group Product Features and Attributes

Table 49. Thales Group Revenue (US$ Million) and Gross Margin (2021-2026)

Table 50. Thales Group Revenue Proportion by Product in 2025

Table 51. Thales Group Revenue Proportion by Application in 2025

Table 52. Thales Group Revenue Proportion by Geographic Area in 2025

Table 53. Thales Group Artificial Intelligence in Pharma and Biotech SWOT Analysis

Table 54. Thales Group Recent Developments

Table 55. IBM Corp. Corporation Information

Table 56. IBM Corp. Description and Major Businesses

Table 57. IBM Corp. Product Features and Attributes

Table 58. IBM Corp. Revenue (US$ Million) and Gross Margin (2021-2026)

Table 59. IBM Corp. Revenue Proportion by Product in 2025

Table 60. IBM Corp. Revenue Proportion by Application in 2025

Table 61. IBM Corp. Revenue Proportion by Geographic Area in 2025

Table 62. IBM Corp. Artificial Intelligence in Pharma and Biotech SWOT Analysis

Table 63. IBM Corp. Recent Developments

Table 64. ForeSee Medical Corporation Information

Table 65. ForeSee Medical Description and Major Businesses

Table 66. ForeSee Medical Product Features and Attributes

Table 67. ForeSee Medical Revenue (US$ Million) and Gross Margin (2021-2026)

Table 68. ForeSee Medical Revenue Proportion by Product in 2025

Table 69. ForeSee Medical Revenue Proportion by Application in 2025

Table 70. ForeSee Medical Revenue Proportion by Geographic Area in 2025

Table 71. ForeSee Medical Artificial Intelligence in Pharma and Biotech SWOT Analysis

Table 72. ForeSee Medical Recent Developments

Table 73. Atomwise Corporation Information

Table 74. Atomwise Description and Major Businesses

Table 75. Atomwise Product Features and Attributes

Table 76. Atomwise Revenue (US$ Million) and Gross Margin (2021-2026)

Table 77. Atomwise Revenue Proportion by Product in 2025

Table 78. Atomwise Revenue Proportion by Application in 2025

Table 79. Atomwise Revenue Proportion by Geographic Area in 2025

Table 80. Atomwise Artificial Intelligence in Pharma and Biotech SWOT Analysis

Table 81. Atomwise Recent Developments

Table 82. Cloud Pharmaceuticals Corporation Information

Table 83. Cloud Pharmaceuticals Description and Major Businesses

Table 84. Cloud Pharmaceuticals Product Features and Attributes

Table 85. Cloud Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)

Table 86. Cloud Pharmaceuticals Recent Developments

Table 87. GNS Healthcare Corporation Information

Table 88. GNS Healthcare Description and Major Businesses

Table 89. GNS Healthcare Product Features and Attributes

Table 90. GNS Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)

Table 91. GNS Healthcare Recent Developments

Table 92. Microsoft Corporation Corporation Information

Table 93. Microsoft Corporation Description and Major Businesses

Table 94. Microsoft Corporation Product Features and Attributes

Table 95. Microsoft Corporation Revenue (US$ Million) and Gross Margin (2021-2026)

Table 96. Microsoft Corporation Recent Developments

Table 97. Novartis AG Corporation Information

Table 98. Novartis AG Description and Major Businesses

Table 99. Novartis AG Product Features and Attributes

Table 100. Novartis AG Revenue (US$ Million) and Gross Margin (2021-2026)

Table 101. Novartis AG Recent Developments

Table 102. NVIDIA Corporation Corporation Information

Table 103. NVIDIA Corporation Description and Major Businesses

Table 104. NVIDIA Corporation Product Features and Attributes

Table 105. NVIDIA Corporation Revenue (US$ Million) and Gross Margin (2021-2026)

Table 106. NVIDIA Corporation Recent Developments

Table 107. Pfizer Corporation Information

Table 108. Pfizer Description and Major Businesses

Table 109. Pfizer Product Features and Attributes

Table 110. Pfizer Revenue (US$ Million) and Gross Margin (2021-2026)

Table 111. Pfizer Recent Developments

Table 112. Recursion Pharmaceuticals Corporation Information

Table 113. Recursion Pharmaceuticals Description and Major Businesses

Table 114. Recursion Pharmaceuticals Product Features and Attributes

Table 115. Recursion Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)

Table 116. Recursion Pharmaceuticals Recent Developments

Table 117. XtalPi Inc Corporation Information

Table 118. XtalPi Inc Description and Major Businesses

Table 119. XtalPi Inc Product Features and Attributes

Table 120. XtalPi Inc Revenue (US$ Million) and Gross Margin (2021-2026)

Table 121. XtalPi Inc Recent Developments

Table 122. Aidoc Corporation Information

Table 123. Aidoc Description and Major Businesses

Table 124. Aidoc Product Features and Attributes

Table 125. Aidoc Revenue (US$ Million) and Gross Margin (2021-2026)

Table 126. Aidoc Recent Developments

Table 127. AliveCor Corporation Information

Table 128. AliveCor Description and Major Businesses

Table 129. AliveCor Product Features and Attributes

Table 130. AliveCor Revenue (US$ Million) and Gross Margin (2021-2026)

Table 131. AliveCor Recent Developments

Table 132. GE Healthcare Corporation Information

Table 133. GE Healthcare Description and Major Businesses

Table 134. GE Healthcare Product Features and Attributes

Table 135. GE Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)

Table 136. GE Healthcare Recent Developments

Table 137. Imagen Technologies Corporation Information

Table 138. Imagen Technologies Description and Major Businesses

Table 139. Imagen Technologies Product Features and Attributes

Table 140. Imagen Technologies Revenue (US$ Million) and Gross Margin (2021-2026)

Table 141. Imagen Technologies Recent Developments

Table 142. Vuno Inc. Corporation Information

Table 143. Vuno Inc. Description and Major Businesses

Table 144. Vuno Inc. Product Features and Attributes

Table 145. Vuno Inc. Revenue (US$ Million) and Gross Margin (2021-2026)

Table 146. Vuno Inc. Recent Developments

Table 147. IDx Technologies Inc. Corporation Information

Table 148. IDx Technologies Inc. Description and Major Businesses

Table 149. IDx Technologies Inc. Product Features and Attributes

Table 150. IDx Technologies Inc. Revenue (US$ Million) and Gross Margin (2021-2026)

Table 151. IDx Technologies Inc. Recent Developments

Table 152. Siemens Healthcare GmbH Corporation Information

Table 153. Siemens Healthcare GmbH Description and Major Businesses

Table 154. Siemens Healthcare GmbH Product Features and Attributes

Table 155. Siemens Healthcare GmbH Revenue (US$ Million) and Gross Margin (2021-2026)

Table 156. Siemens Healthcare GmbH Recent Developments

Table 157. Neural Analytics Corporation Information

Table 158. Neural Analytics Description and Major Businesses

Table 159. Neural Analytics Product Features and Attributes

Table 160. Neural Analytics Revenue (US$ Million) and Gross Margin (2021-2026)

Table 161. Neural Analytics Recent Developments

Table 162. Insilico Medicine Corporation Information

Table 163. Insilico Medicine Description and Major Businesses

Table 164. Insilico Medicine Product Features and Attributes

Table 165. Insilico Medicine Revenue (US$ Million) and Gross Margin (2021-2026)

Table 166. Insilico Medicine Recent Developments

Table 167. Technologies, Platforms and Infrastructure

Table 168. Distributors List

Table 169. Market Trends and Market Evolution

Table 170. Market Drivers and Opportunities

Table 171. Market Challenges, Risks, and Restraints

Table 172. Research Programs/Design for This Report

Table 173. Key Data Information from Secondary Sources

Table 174. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 2. AI Drug Discovery Product Picture

Figure 3. Preclinical Research AI Product Picture

Figure 4. Clinical Trial AI Product Picture

Figure 5. Others Product Picture

Figure 6. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Technology, 2021 vs 2025 vs 2032 (US$ Million)

Figure 7. Machine Learning Product Picture

Figure 8. Deep Learning Product Picture

Figure 9. Generative AI Product Picture

Figure 10. Computer Vision Product Picture

Figure 11. Others Product Picture

Figure 12. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)

Figure 13. Global Artificial Intelligence in Pharma and Biotech Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Figure 14. Oncology

Figure 15. Neurology

Figure 16. Immunology

Figure 17. Rare Diseases

Figure 18. Infectious Diseases

Figure 19. Others

Figure 20. Artificial Intelligence in Pharma and Biotech Report Years Considered

Figure 21. Global Artificial Intelligence in Pharma and Biotech Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 23. Global Artificial Intelligence in Pharma and Biotech Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 24. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share by Region (2021-2032)

Figure 25. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share Ranking (2025)

Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 27. AI Drug Discovery Revenue-Based Market Share by Player in 2025

Figure 28. Preclinical Research AI Revenue-Based Market Share by Player in 2025

Figure 29. Clinical Trial AI Revenue-Based Market Share by Player in 2025

Figure 30. Others Revenue-Based Market Share by Player in 2025

Figure 31. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share by Type (2021-2032)

Figure 32. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share by Technology (2021-2032)

Figure 33. Global Artificial Intelligence in Pharma and Biotech Revenue-Based Market Share by Application (2021-2032)

Figure 34. North America Artificial Intelligence in Pharma and Biotech Revenue YoY (US$ Million), 2021-2032

Figure 35. North America Top 5 Players Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) in 2025

Figure 36. North America Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) by Application (2021-2032)

Figure 37. US Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 38. Canada Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 39. Mexico Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 40. Europe Artificial Intelligence in Pharma and Biotech Revenue YoY (US$ Million), 2021-2032

Figure 41. Europe Top 5 Players Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) in 2025

Figure 42. Europe Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) by Application (2021-2032)

Figure 43. Germany Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 44. France Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 45. U.K. Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 46. Italy Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 47. Russia Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 48. Asia-Pacific Artificial Intelligence in Pharma and Biotech Revenue YoY (US$ Million), 2021-2032

Figure 49. Asia-Pacific Top 8 Players Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) in 2025

Figure 50. Asia-Pacific Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) by Application (2021-2032)

Figure 51. Indonesia Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 52. Japan Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 53. South Korea Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 54. Australia Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 55. India Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 56. Indonesia Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 57. Vietnam Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 58. Malaysia Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 59. Philippines Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 60. Singapore Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 61. Central and South America Artificial Intelligence in Pharma and Biotech Revenue YoY (US$ Million), 2021-2032

Figure 62. Central and South America Top 5 Players Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) in 2025

Figure 63. Central and South America Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) by Application (2021-2032)

Figure 64. Brazil Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 65. Argentina Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 66. Middle East and Africa Artificial Intelligence in Pharma and Biotech Revenue YoY (US$ Million), 2021-2032

Figure 67. Middle East and Africa Top 5 Players Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) in 2025

Figure 68. Middle East and Africa Artificial Intelligence in Pharma and Biotech Revenue (US$ Million) by Application (2021-2032)

Figure 69. GCC Countries Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 70. Israel Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 71. Egypt Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 72. South Africa Artificial Intelligence in Pharma and Biotech Revenue (US$ Million), 2021-2032

Figure 73. Artificial Intelligence in Pharma and Biotech Value Chain Mapping

Figure 74. Channels of Distribution (Direct Vs Distribution)

Figure 75. Bottom-up and Top-down Approaches for This Report

Figure 76. Data Triangulation

Figure 77. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Artificial Intelligence in Pharma and Biotech market size from 2026 to 2032? zhanKai

The annual compound growth rate of the global Artificial Intelligence in Pharma and Biotech market is 31.0% 2026 to 2032.

Which region is expected to have the highest market share? shouQi

What was the global market size of Artificial Intelligence in Pharma and Biotech in 2026? shouQi

Which companies rank high in the global Artificial Intelligence in Pharma and Biotech market? shouQi

What was the global market size of Artificial Intelligence in Pharma and Biotech in 2032? shouQi

Related Reports

Global Artificial Intelligence in Pharma and Biotech Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Artificial Intelligence in Pharma and Biotech market size was US$ 2130 million in 2025 and is forecast to reach a readjusted size of US$ 18011 million by 2032 with a CAGR of 31.0% during the forecast period 2026-2032.
Published Date: 2026-07-30
Pages: 149
USD 4250.00
(Single User License)
Global Artificial Intelligence in Pharma and Biotech Market Research Report 2026
The global Artificial Intelligence in Pharma and Biotech market was valued at US$ 2130 million in 2025 and is anticipated to reach US$ 18011 million by 2032, at a CAGR of 31.0% from 2026 to 2032.
Published Date: 2026-07-30
Pages: 147
USD 2900.00
(Single User License)
Artificial Intelligence in Pharma and Biotech - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Artificial Intelligence in Pharma and Biotech was estimated to be worth US$ 2130 million in 2025 and is projected to reach US$ 18011 million, growing at a CAGR of 31.0% from 2026 to 2032.
Published Date: 2026-07-30
Pages: 144
USD 3950.00
(Single User License)

Global Artificial Intelligence in Pharma and Biotech Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Artificial Intelligence in Pharma and Biotech market size was US$ 2130 million in 2025 and is forecast to reach a readjusted size of US$ 18011 million by 2032 with a CAGR of 31.0% during the forecast period 2026-2032.
Published: 2026-07-30
Pages: 149
USD 4250.00 (Single User License)
Global Artificial Intelligence in Pharma and Biotech Market Research Report 2026
The global Artificial Intelligence in Pharma and Biotech market was valued at US$ 2130 million in 2025 and is anticipated to reach US$ 18011 million by 2032, at a CAGR of 31.0% from 2026 to 2032.
Published: 2026-07-30
Pages: 147
USD 2900.00 (Single User License)
Artificial Intelligence in Pharma and Biotech - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Artificial Intelligence in Pharma and Biotech was estimated to be worth US$ 2130 million in 2025 and is projected to reach US$ 18011 million, growing at a CAGR of 31.0% from 2026 to 2032.
Published: 2026-07-30
Pages: 144
USD 3950.00 (Single User License)